NCT05778747 (H2HYoga) is a NA clinical trial of Heart to Heart Yoga in Heart Failure, sponsored by Misook L. Chung.

Who is sponsoring NCT05778747?

NCT05778747 is sponsored by Misook L. Chung.

What drugs are being tested in NCT05778747?

Interventions in NCT05778747: Heart to Heart Yoga.

What condition does NCT05778747 study?

NCT05778747 studies Heart Failure, Caregiver Burden, Depression, Anxiety, Stress.

Is NCT05778747 still recruiting?

NCT05778747 is currently completed. Last updated 30 November 2023.

Last reviewed 2023-11-30 · How we verify

NCT05778747: H2HYoga

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Feasibility of the Heart to Heart Yoga Program

Completed NA Last updated 30 November 2023

What this trial tests

NA trial testing Heart to Heart Yoga in Heart Failure in 38 participants. Completed in 13 October 2023.

Timeline

15 October 2022

Primary endpoint
13 October 2023

13 October 2023

Quick facts

Lead sponsor	Misook L. Chung
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	38
Start date	15 October 2022
Primary completion	13 October 2023
Estimated completion	13 October 2023
Sites	1 location across United States

Drugs / interventions tested

Heart to Heart Yoga

Conditions studied

Heart Failure — all drugs for Heart Failure →
Caregiver Burden — all drugs for Caregiver Burden →
Depression — all drugs for Depression →
Anxiety — all drugs for Anxiety →

Sponsor

Misook L. Chung

Who can join

Adults 18 to 99, any sex, with Heart Failure or Caregiver Burden. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A two-group (intervention vs. usual care), randomized controlled design will be used to determine the feasibility and acceptability of the intervention, the Heart2Heart program, and determine efficacy on physical and psychological outcomes in patients with heart failure (HF) and caregivers. A total of 20 patients with HF and 20 caregivers (n= 40) will be randomly assigned to the intervention or usual care group stratified by patient and caregiver groups. Only participants in the intervention will be asked to attend the 12-week sessions (two sessions per week; a total of 24 sessions in 12 weeks) via video conferencing (i.e., ZOOM). The short-term intervention efficacy will be assessed following week of the completion of 12-weeks sessions. Primary psychological outcomes include depressive symptoms, anxiety, stress, and quality of life. Primary physical outcomes include physical activity level, sleep quality, and perceived symptoms.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Heart Failure

Currently open trials in the same condition.

NCT06118983 — Improving TRansitions ANd OutcomeS for Heart FailurE Patients in Home Health CaRe (I-TRANSFER-HF) · NA · recruiting
NCT07496372 — Efficacy and Safety of Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Injection (HiCM-188) in Advanced Heart · Phase 3 · recruiting
NCT07527156 — Prolonged Nasogastric Administration of Ketones in Decompensated Heart Failure · Phase 4 · recruiting
NCT07263035 — Urine Sodium-Driven Diuretic Adjustment Strategy in Acute Decompensated Heart Failure · Phase 4 · recruiting
NCT07531966 — Vascular Complications After Kidney Transplantation · recruiting

Other Misook L. Chung trials

Trials by the same sponsor.

NCT04076280 — Sodium Watchers Program - Hypertension · NA · completed
NCT03560206 — Effects of Family Sodium Watcher Program on Outcomes in Heart Failure Patient-Family Caregiver Dyads · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05778747 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Misook L. Chung
Last refreshed: 30 November 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05778747.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing